Costs Associated with Exit/Disposal Form 8 K

Item 2.05. Costs Associated with Exit or Disposal Activities.

On July 22, 2024, Viracta Therapeutics, Inc. (the "Company"), committed to and implemented a reduction in force, to be completed in August 2024, that impacted approximately 23% of the Company's workforce.

The Company expects to recognize approximately $0.7 million in total expenses for severance and related benefits for employees laid off under the reduction in force, consisting primarily of severance payments and continued healthcare benefits for a specific period of time. The Company may also incur other charges or cash expenditures not currently contemplated due to events that may occur as a result of, or associated with, the reduction in force.

Additional details will be provided as applicable in the Company's future filings with the Securities and Exchange Commission.

Forward-Looking Statements

Certain of the statements made in this report are forward looking, such as those, among others, relating to the expected total expenses related to the reduction in force. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Forward-looking statements are subject to the occurrence of many events outside of the Company's control. Actual results and the timing of events may differ materially from those contemplated by such forward-looking statements due to numerous factors that involve substantial known and unknown risks and uncertainties. These risks and uncertainties include, among other things, the risk that the expenses related to the reduction in force may be greater than anticipated. More information about the risks and uncertainties faced by the Company is contained under the caption "Risk Factors" in the Company's Quarterly Report on Form 10-Q filed with the SEC on May 9, 2024. You are cautioned not to place undue reliance on forward-looking statements which are current only as of the date hereof. Except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.